Microvascular thrombosis: A serious and deadly pathologic process in multiple diseases

Seminars in Thrombosis and Hemostasis

Volumn 37, Issue 8, 2011, Pages 961-977

  Kwaan, Hau C ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

disseminated intravascular coagulation; hypercoagulable state; inflammation; sepsis; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; COLD AGGLUTININ;

ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BLOOD FLOW; CHICKENPOX; CLINICAL FEATURE; COLD AGGLUTININ SYNDROME; DISEASE SEVERITY; ENDOTHELIUM INJURY; ERYTHROCYTE AGGREGATION; FATALITY; FULMINATING PURPURA; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INJURY; LEUKOSTASIS; MALARIA; MICROTHROMBUS; MICROVASCULATURE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RADIATION INJURY; REPERFUSION; SEPSIS; SUBARACHNOID HEMORRHAGE; SURGICAL TECHNIQUE; THROMBOCYTE AGGREGATION; THROMBOTIC THROMBOCYTOPENIC PURPURA; TUMOR VASCULARIZATION;

CHRONIC DISEASE; HUMANS; MICROVESSELS; THROMBOSIS; THROMBOTIC MICROANGIOPATHIES;

EID: 84555204282     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0031-1297375     Document Type: Article

References (197)

1. Aird W C. Spatial and temporal dynamics of the endothelium. J Thromb Haemost 2005 3 7 1392-1406 (Pubitemid 41725195)
2. Lipowsky H H. Microvascular rheology and hemodynamics. Microcirculation 2005 12 1 5-15 (Pubitemid 40450614)
3. Baskurt O K., Meiselman H J. Blood rheology and hemodynamics. Semin Thromb Hemost 2003 29 5 435-450 (Pubitemid 37352643)
4. Aird W C. Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. Circ Res 2007 100 2 158-173 (Pubitemid 46208717)
5. Aird W C. Phenotypic heterogeneity of the endothelium: II. Representative vascular beds. Circ Res 2007 100 2 174-190 (Pubitemid 46208718)
6. Pries A R., Kuebler W M. Normal endothelium. Handb Exp Pharmacol 2006 176 176 Pt 1 1-40
7. Kwaan H C., Samama M M. The significance of endothelial heterogeneity in thrombosis and hemostasis. Semin Thromb Hemost 2010 36 3 286-300
8. Ishii H, Salem H H., Bell C E., Laposata E A., Majerus P W. Thrombomodulin, an endothelial anticoagulant protein, is absent from the human brain. Blood 1986 67 2 362-365 (Pubitemid 16164649)
9. Esmon C T., Gu J M., Xu J, Qu D, Stearns-Kurosawa D J., Kurosawa S. Regulation and functions of the protein C anticoagulant pathway. Haematologica 1999 84 4 363-368 (Pubitemid 29474352)
10. Lippi G, Franchini M. Pathogenesis of venous thromboembolism: when the cup runneth over. Semin Thromb Hemost 2008 34 8 747-761
11. Lippi G, Franchini M, Favaloro E J. Unsuspected triggers of venous thromboembolismtrivial or not so trivial? Semin Thromb Hemost 2009 35 7 597-604
12. Virchow R. Phlogose und Thrombose in Gefabsystem. In: Gesammelte Abhandlungen zur Wissenschaftlichen Medizin. Frankfurt, Germany Von Meidinger Sohn 1856 458
13. Levi M, Schultz M, van der Poll T. Disseminated intravascular coagulation in infectious disease. Semin Thromb Hemost 2010 36 4 367-377
14. Galindo M, Gonzalo E, Martinez-Vidal M P. et al. Immunohistochemical detection of intravascular platelet microthrombi in patients with lupus nephritis and anti-phospholipid antibodies. Rheumatology (Oxford) 2009 48 8 1003-1007
15. Nagy J A., Chang S H., Shih S C., Dvorak A M., Dvorak H F. Heterogeneity of the tumor vasculature. Semin Thromb Hemost 2010 36 3 321-331
16. Rubin D B., Drab E A., Ward W F. Physiological and biochemical markers of the endothelial cell response to irradiation. Int J Radiat Biol 1991 60 1-2 29-32
17. Kloner R A., Ganote C E., Jennings R B. The no-reflow phenomenon after temporary coronary occlusion in the dog. J Clin Invest 1974 54 6 1496-1508
18. Brands M T., van den Bosch S C., Dieleman F J., Bergé S J., Merkx M A. Prevention of thrombosis after microvascular tissue transfer in the head and neck. A review of the literature and the state of affairs in Dutch Head and Neck Cancer Centers. Int J Oral Maxillofac Surg 2010 39 2 101-106
19. Lecoq J P., Senard M, Hartstein G M., Lamy M, Heymans O. Thromboprophylaxis in microsurgery. Acta Chir Belg 2006 106 2 158-164 (Pubitemid 43709757)
20. Kwaan H C., Bongu A. The hyperviscosity syndromes. Semin Thromb Hemost 1999 25 2 199-208 (Pubitemid 29227148)
21. Esmon C T. The impact of the inflammatory response on coagulation. Thromb Res 2004 114 5-6 321-327 (Pubitemid 39422563)
22. Esmon C T. The interactions between inflammation and coagulation. Br J Haematol 2005 131 4 417-430 (Pubitemid 43899639)
23. Levi M. The coagulant response in sepsis and inflammation. Hamostaseologie 2010 30 1 10-12, 1416
24. Bevilacqua M P., Pober J S., Majeau G R., Fiers W, Cotran R S., Gimbrone M A. Jr. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci U S A 1986 83 12 4533-4537 (Pubitemid 16057083)
25. Coughlin S R. Thrombin signalling and protease-activated receptors. Nature 2000 407 6801 258-264
26. Bevilacqua M P., Nelson R M. Endothelial-leukocyte adhesion molecules in inflammation and metastasis. Thromb Haemost 1993 70 1 152-154 (Pubitemid 23225469)
27. Gando S. Microvascular thrombosis and multiple organ dysfunction syndrome. Crit Care Med 2010 38 2, Suppl S35-S42
28. Lee C C., Marill K A., Carter W A., Crupi R S. A current concept of trauma-induced multiorgan failure. Ann Emerg Med 2001 38 2 170-176 (Pubitemid 32702284)
29. Hertig A, Rondeau E. Role of the coagulation/fibrinolysis system in fibrin-associated glomerular injury. J Am Soc Nephrol 2004 15 4 844-853 (Pubitemid 38375303)
30. Welty-Wolf K E., Carraway M S., Ortel T L., Piantadosi C A. Coagulation and inflammation in acute lung injury. Thromb Haemost 2002 88 1 17-25 (Pubitemid 34752261)
31. Dhainaut J F., Marin N, Mignon A, Vinsonneau C. Hepatic response to sepsis: interaction between coagulation and inflammatory processes. Crit Care Med 2001 29 7, Suppl S42-S47 (Pubitemid 32681581)
32. Papadopoulos M C., Davies D C., Moss R F., Tighe D, Bennett E D. Pathophysiology of septic encephalopathy: a review. Crit Care Med 2000 28 8 3019-3024
33. Stegmayr B G. Apheresis as therapy for patients with severe sepsis and multiorgan dysfunction syndrome. Ther Apher 2001 5 2 123-127 (Pubitemid 32428801)
34. Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999 341 8 586-592 (Pubitemid 29384168)
35. ten Cate H, Timmerman J J., Levi M. The pathophysiology of disseminated intravascular coagulation. Thromb Haemost 1999 82 2 713-717
36. Lippi G, Cervellin G. Disseminated intravascular coagulation in trauma injuries. Semin Thromb Hemost 2010 36 4 378-387
37. Kojima M, Shimamura K, Mori N, Oka K, Nakazawa M. A histological study on microthrombi in autopsy cases of DIC. Bibl Haematol 1983 49 95-106 (Pubitemid 14202216)
38. Shimamura K, Oka K, Nakazawa M, Kojima M. Distribution patterns of microthrombi in disseminated intravascular coagulation. Arch Pathol Lab Med 1983 107 10 543-547 (Pubitemid 13008611)
39. Schouten M, Wiersinga W J., Levi M, van der Poll T. Inflammation, endothelium, and coagulation in sepsis. J Leukoc Biol 2008 83 3 536-545 (Pubitemid 351966862)
40. Osterud B. Tissue factor expression by monocytes: regulation and pathophysiological roles. Blood Coagul Fibrinolysis 1998 9 Suppl 1 S9-S14 (Pubitemid 28511560)
41. Meziani F, Delabranche X, Asfar P, Toti F. Bench-to-bedside review: circulating microparticlesa new player in sepsis? Crit Care 2010 14 5 236
42. Soriano A O., Jy W, Chirinos J A. et al. Levels of endothelial and platelet microparticles and their interactions with leukocytes negatively correlate with organ dysfunction and predict mortality in severe sepsis. Crit Care Med 2005 33 11 2540-2546 (Pubitemid 41682106)
43. McEver R P. GMP-140: a receptor for neutrophils and monocytes on activated platelets and endothelium. J Cell Biochem 1991 45 2 156-161
44. Klintman D, Li X, Thorlacius H. Important role of P-selectin for leukocyte recruitment, hepatocellular injury, and apoptosis in endotoxemic mice. Clin Diagn Lab Immunol 2004 11 1 56-62 (Pubitemid 38090652)
45. Ward P A. Role of the complement in experimental sepsis. J Leukoc Biol 2008 83 3 467-470 (Pubitemid 351966852)
46. Laudes I J., Chu J C., Huber-Lang M et al. Expression and function of C5a receptor in mouse microvascular endothelial cells. J Immunol 2002 169 10 5962-5970 (Pubitemid 35299387)
47. Esmon C T., Fukudome K, Mather T et al. Inflammation, sepsis, and coagulation. Haematologica 1999 84 3 254-259 (Pubitemid 29476931)
48. Levi M, Lowenberg E, Meijers J C. Recombinant anticoagulant factors for adjunctive treatment of sepsis. Semin Thromb Hemost 2010 36 5 550-557
49. Bernard G R., Vincent J L., Laterre P F. et al, Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001 344 10 699-709 (Pubitemid 32204987)
50. Ely E W., Laterre P F., Angus D C. et al, PROWESS Investigators. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med 2003 31 1 12-19 (Pubitemid 36151143)
51. Dhainaut J F., Yan S B., Joyce D E. et al. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost 2004 2 11 1924-1933 (Pubitemid 40192745)
52. Abraham E, Laterre P F., Garg R et al, Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005 353 13 1332-1341 (Pubitemid 41362701)
53. Levi M, Levy M, Williams M D. et al, Xigris and Prophylactic HepaRin Evaluation in Severe Sepsis (XPRESS) Study Group. Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated). Am J Respir Crit Care Med 2007 176 5 483-490 (Pubitemid 47358102)
54. Costa V, Brophy J M. Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysis. BMC Anesthesiol 2007 7 5
55. Barie P S. All in for a huge pot: the PROWESS-SHOCK trial for refractory septic shock. Surg Infect (Larchmt) 2007 8 5 491-494
56. Barie P S. Current role of activated protein C therapy for severe sepsis and septic shock. Curr Infect Dis Rep 2008 10 5 368-376
57. Bernard G R., Margolis B D., Shanies H M. et al, Extended Evaluation of Recombinant Human Activated Protein C United States Investigators. Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis. Chest 2004 125 6 2206-2216 (Pubitemid 38788191)
58. Leitner J M., Firbas C, Mayr F B., Reiter R A., Steinlechner B, Jilma B. Recombinant human antithrombin inhibits thrombin formation and interleukin 6 release in human endotoxemia. Clin Pharmacol Ther 2006 79 1 23-34 (Pubitemid 43069576)
59. Warren B L., Eid A, Singer P et al, KyberSept Trial Study Group. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001 286 15 1869-1878 (Pubitemid 33010239)
60. Ott I, Miyagi Y, Miyazaki K et al. Reversible regulation of tissue factor-induced coagulation by glycosyl phosphatidylinositol-anchored tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol 2000 20 3 874-882 (Pubitemid 30151706)
61. Brandtzaeg P, Sandset P M., Joø G B., Ovstebø R, Abildgaard U, Kierulf P. The quantitative association of plasma endotoxin, antithrombin, protein C, extrinsic pathway inhibitor and fibrinopeptide A in systemic meningococcal disease. Thromb Res 1989 55 4 459-470 (Pubitemid 19215683)
62. Abraham E, Reinhart K, Opal S et al, OPTIMIST Trial Study Group. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003 290 2 238-247 (Pubitemid 37430063)
63. van der Poll T, Levi M, Büller H R. et al. Fibrinolytic response to tumor necrosis factor in healthy subjects. J Exp Med 1991 174 3 729-732
64. Carmeliet P, Schoonjans L, Kieckens L et al. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994 368 6470 419-424 (Pubitemid 24115347)
65. Bajzar L, Jain N, Wang P, Walker J B. Thrombin activatable fibrinolysis inhibitor: not just an inhibitor of fibrinolysis. Crit Care Med 2004 32 5, Suppl S320-S324
66. Leung L L., Nishimura T, Myles T. Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B (or TAFI). Adv Exp Med Biol 2008 632 61-69
67. Kwaan H C., Gordon L I. Thrombotic microangiopathy in the cancer patient. Acta Haematol 2001 106 1-2 52-56 (Pubitemid 32830516)
68. Elliott M A., Letendre L, Gastineau D A., Winters J L., Pruthi R K., Heit J A. Cancer-associated microangiopathic hemolytic anemia with thrombocytopenia: an important diagnostic consideration. Eur J Haematol 2010 85 1 43-50
69. Zakarija A. Thrombotic microangiopathy syndromes. Cancer Treat Res 2009 148 115-136
70. Gordon L I., Kwaan H C. Cancer- and drug-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Semin Hematol 1997 34 2 140-147 (Pubitemid 27175072)
71. Kwaan H C., Boggio L N. The clinical spectrum of thrombotic thrombocytopenic purpura. Semin Thromb Hemost 2005 31 6 673-680 (Pubitemid 43063085)
72. Karpman D, Sartz L, Johnson S. Pathophysiology of typical hemolytic uremic syndrome. Semin Thromb Hemost 2010 36 6 575-585
73. Baronzio G, Freitas I, Kwaan H C. Tumor microenvironment and hemorheological abnormalities. Semin Thromb Hemost 2003 29 5 489-497 (Pubitemid 37352649)
74. Brat D J., Van Meir E G. Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma. Lab Invest 2004 84 4 397-405 (Pubitemid 41656467)
75. Wang J, Weiss I, Svoboda K, Kwaan H C. Thrombogenic role of cells undergoing apoptosis. Br J Haematol 2001 115 2 382-391 (Pubitemid 34203507)
76. Rak J. Microparticles in cancer. Semin Thromb Hemost 2010 36 8 888-906
77. Kwaan H C., Rego E M. Role of microparticles in the hemostatic dysfunction in acute promyelocytic leukemia. Semin Thromb Hemost 2010 36 8 917-924
78. Key N S., Kwaan H C. Microparticles in thrombosis and hemostasis. Semin Thromb Hemost 2010 36 8 805-806
79. Myhre-Jensen O, Hansen E S., Butrago B. Renal microthrombosis. Incidence in 500 consecutive autopsies. Clinico-pathological relations. Acta Pathol Microbiol Scand [A] 1972 80 3 403-411
80. Shih H M., Lin C C., Shiao Y W. Pulmonary tumor thrombotic microangiopathy. Am J Emerg Med 2011 29 2 241, e3-e4
81. Chinen K, Tokuda Y, Fujiwara M, Fujioka Y. Pulmonary tumor thrombotic microangiopathy in patients with gastric carcinoma: an analysis of 6 autopsy cases and review of the literature. Pathol Res Pract 2010 206 10 682-689
82. Tehrani M, Friedman T M., Olson J J., Brat D J. Intravascular thrombosis in central nervous system malignancies: a potential role in astrocytoma progression to glioblastoma. Brain Pathol 2008 18 2 164-171 (Pubitemid 351430394)
83. Hallahan D, Clark E T., Kuchibhotla J, Gewertz B L., Collins T. E-selectin gene induction by ionizing radiation is independent of cytokine induction. Biochem Biophys Res Commun 1995 217 3 784-795 (Pubitemid 26019725)
84. Jahroudi N, Ardekani A M., Greenberger J S. Ionizing irradiation increases transcription of the von Willebrand factor gene in endothelial cells. Blood 1996 88 10 3801-3814 (Pubitemid 26383102)
85. Verheij M, Dewit L G., van Mourik J A. The effect of ionizing radiation on endothelial tissue factor activity and its cellular localization. Thromb Haemost 1995 73 5 894-895
86. Hauer-Jensen M, Fink L M., Wang J. Radiation injury and the protein C pathway. Crit Care Med 2004 32 5, Suppl S325-S330
87. Astedt B, Bergentz S E., Svanberg L. Effect of irradiation on the plasminogen activator content in rat vessels. Experientia 1974 30 12 1466-1467
88. Dropcho E J. Neurotoxicity of radiation therapy. Neurol Clin 2010 28 1 217-234
89. Lyons A, Ghazali N. Osteoradionecrosis of the jaws: current understanding of its pathophysiology and treatment. Br J Oral Maxillofac Surg 2008 46 8 653-660
90. Madrid C, Abarca M, Bouferrache K. Osteoradionecrosis: an update. Oral Oncol 2010 46 6 471-474
91. Kwaan H C. Miscellaneous secondary thrombotic microangiopathy. Semin Hematol 1987 24 3 141-147
92. Kwaan H C. Thrombotic thrombocytopenic purpura: a diagnostic and therapeutic challenge. Semin Thromb Hemost 2005 31 6 615-624 (Pubitemid 43063079)
93. Mitra D, Jaffe E A., Weksler B, Hajjar K A., Soderland C, Laurence J. Thrombotic thrombocytopenic purpura and sporadic hemolytic-uremic syndrome plasmas induce apoptosis in restricted lineages of human microvascular endothelial cells. Blood 1997 89 4 1224-1234 (Pubitemid 27079986)
94. Laurence J, Mitra D. Apoptosis of microvascular endothelial cells in the pathophysiology of thrombotic thrombocytopenic purpura/sporadic hemolytic uremic syndrome. Semin Hematol 1997 34 2 98-105 (Pubitemid 27175067)
95. Zipfel P F., Heinen S, Skerka C. Thrombotic microangiopathies: new insights and new challenges. Curr Opin Nephrol Hypertens 2010 19 4 372-378
96. Louise C B., Obrig T G. Shiga toxin-associated hemolytic-uremic syndrome: combined cytotoxic effects of Shiga toxin, interleukin-1 beta, and tumor necrosis factor alpha on human vascular endothelial cells in vitro. Infect Immun 1991 59 11 4173-4179
97. Louise C B., Obrig T G. Human renal microvascular endothelial cells as a potential target in the development of the hemolytic uremic syndrome as related to fibrinolysis factor expression, in vitro. Microvasc Res 1994 47 3 377-387 (Pubitemid 24207594)
98. Dragon-Durey M A., Sethi S K., Bagga A et al. Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol 2010 21 12 2180-2187
99. Le Quintrec M, Roumenina L, Noris M, Frémeaux-Bacchi V. Atypical hemolytic uremic syndrome associated with mutations in complement regulator genes. Semin Thromb Hemost 2010 36 6 641-652
100. Heinen S, Hartmann A, Lauer N et al. Factor H-related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation. Blood 2009 114 12 2439-2447
101. Kwaan H C. Miscellaneous secondary thrombotic microangiopathy. Semin Hematol 1987 24 3 141-147
102. Kelton J G., Warkentin T E. Heparin-induced thrombocytopenia: a historical perspective. Blood 2008 112 7 2607-2616
103. Kwaan H C., Sakurai S. Endothelial cell hyperplasia contributes to thrombosis in heparin-induced thrombocytopenia. Semin Thromb Hemost 1999 25 Suppl 1 23-27 (Pubitemid 29230561)
104. Baskurt O K., Meiselman H J. Blood rheology and hemodynamics. Semin Thromb Hemost 2003 29 5 435-450 (Pubitemid 37352643)
105. Kwaan H C., Wang J. Hyperviscosity in polycythemia vera and other red cell abnormalities. Semin Thromb Hemost 2003 29 5 451-458 (Pubitemid 37352644)
106. Newton C R., Marsh K, Peshu N, Kirkham F J. Perturbations of cerebral hemodynamics in Kenyans with cerebral malaria. Pediatr Neurol 1996 15 1 41-49 (Pubitemid 26268813)
107. Beare N A., Harding S P., Taylor T E., Lewallen S, Molyneux M E. Perfusion abnormalities in children with cerebral malaria and malarial retinopathy. J Infect Dis 2009 199 2 263-271
108. Buffet P A., Safeukui I, Deplaine G et al. The pathogenesis of Plasmodium falciparum malaria in humans: insights from splenic physiology. Blood 2011 117 2 381-392
109. Grau G E., Mackenzie C D., Carr R A. et al. Platelet accumulation in brain microvessels in fatal pediatric cerebral malaria. J Infect Dis 2003 187 3 461-466 (Pubitemid 36184587)
110. Cox D, McConkey S. The role of platelets in the pathogenesis of cerebral malaria. Cell Mol Life Sci 2010 67 4 557-568
111. Baruch D I., Gormely J A., Ma C, Howard R J., Pasloske B L. Plasmodium falciparum erythrocyte membrane protein 1 is a parasitized erythrocyte receptor for adherence to CD36, thrombospondin, and intercellular adhesion molecule 1. Proc Natl Acad Sci U S A 1996 93 8 3497-3502 (Pubitemid 26125649)
112. Chakravorty S J., Hughes K R., Craig A G. Host response to cytoadherence in Plasmodium falciparum. Biochem Soc Trans 2008 36 Pt 2 221-228 (Pubitemid 351570593)
113. García F, Cebrián M, Dgedge M et al. Endothelial cell activation in muscle biopsy samples is related to clinical severity in human cerebral malaria. J Infect Dis 1999 179 2 475-483 (Pubitemid 29086652)
114. Francischetti I M., Seydel K B., Monteiro R Q. et al. Plasmodium falciparum-infected erythrocytes induce tissue factor expression in endothelial cells and support the assembly of multimolecular coagulation complexes. J Thromb Haemost 2007 5 1 155-165 (Pubitemid 44921081)
115. Francischetti I M., Seydel K B., Monteiro R Q. Blood coagulation, inflammation, and malaria. Microcirculation 2008 15 2 81-107 (Pubitemid 351228635)
116. Combes V, Taylor T E., Juhan-Vague I et al. Circulating endothelial microparticles in malawian children with severe falciparum malaria complicated with coma. JAMA 2004 291 21 2542-2544 (Pubitemid 38702769)
117. Milner D A. Jr. Rethinking cerebral malaria pathology. Curr Opin Infect Dis 2010 23 5 456-463
118. Kato G J., Hebbel R P., Steinberg M H., Gladwin M T. Vasculopathy in sickle cell disease: biology, pathophysiology, genetics, translational medicine, and new research directions. Am J Hematol 2009 84 9 618-625
119. Morris C R. Mechanisms of vasculopathy in sickle cell disease and thalassemia. Hematology (Am Soc Hematol Educ Program) 2008 177-185
120. Morris C R., Kato G J., Poljakovic M et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA 2005 294 1 81-90 (Pubitemid 41002842)
121. Francis R B. Jr. Platelets, coagulation, and fibrinolysis in sickle cell disease: their possible role in vascular occlusion. Blood Coagul Fibrinolysis 1991 2 2 341-353
122. Peters M, Plaat B E., ten Cate H, Wolters H J., Weening R S., Brandjes D P. Enhanced thrombin generation in children with sickle cell disease. Thromb Haemost 1994 71 2 169-172 (Pubitemid 24047320)
123. Key N S., Slungaard A, Dandelet L et al. Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood 1998 91 11 4216-4223 (Pubitemid 28261985)
124. Kurantsin-Mills J, Ofosu F A., Safa T K., Siegel R S., Lessin L S. Plasma factor VII and thrombin-antithrombin III levels indicate increased tissue factor activity in sickle cell patients. Br J Haematol 1992 81 4 539-544
125. Nsiri B, Gritli N, Bayoudh F, Messaoud T, Fattoum S, Machghoul S. Abnormalities of coagulation and fibrinolysis in homozygous sickle cell disease. Hematol Cell Ther 1996 38 3 279-284 (Pubitemid 26291422)
126. Kurantsin-Mills J, Ibe B O., Natta C L., Raj J U., Siegel R S., Lessin L S. Elevated urinary levels of thromboxane and prostacyclin metabolities in sickle cell disease reflects activated platelets in the circulation. Br J Haematol 1994 87 3 580-585 (Pubitemid 24230026)
127. Ataga K I., Orringer E P. Hypercoagulability in sickle cell disease: a curious paradox. Am J Med 2003 115 9 721-728 (Pubitemid 38032666)
128. Gladwin M T., Kato G J. Hemolysis-associated hypercoagulability in sickle cell disease: the plot (and blood) thickens! Haematologica 2008 93 1 1-3 (Pubitemid 351156142)
129. Gladwin M T., Vichinsky E. Pulmonary complications of sickle cell disease. N Engl J Med 2008 359 21 2254-2265
130. Bunn H F., Nathan D G., Dover G J. et al. Pulmonary hypertension and nitric oxide depletion in sickle cell disease. Blood 2010 116 5 687-692
131. Gordeuk V R., Campbell A, Rana S et al. Relationship of erythropoietin, fetal hemoglobin, and hydroxyurea treatment to tricuspid regurgitation velocity in children with sickle cell disease. Blood 2009 114 21 4639-4644
132. Machado R F., Martyr S, Kato G J. et al. Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. Br J Haematol 2005 130 3 445-453 (Pubitemid 43899595)
133. Rose V L., Kwaan H C. Anti-Pr cold hemagglutination associated with livedo reticularis. Am J Hematol 1985 19 4 419-421 (Pubitemid 15004925)
134. Ruch J, McMahon B, Ramsey G, Kwaan H C. Catastrophic multiple organ ischemia due to an anti-Pr cold agglutinin developing in a patient with mixed cryoglobulinemia after treatment with rituximab. Am J Hematol 2009 84 2 120-122
135. Blum W, Porcu P. Therapeutic apheresis in hyperleukocytosis and hyperviscosity syndrome. Semin Thromb Hemost 2007 33 4 350-354 (Pubitemid 46878107)
136. Porcu P, Danielson C F., Orazi A, Heerema N A., Gabig T G., McCarthy L J. Therapeutic leukapheresis in hyperleucocytic leukaemias: lack of correlation between degree of cytoreduction and early mortality rate. Br J Haematol 1997 98 2 433-436 (Pubitemid 27345121)
137. Vaughan W P., Kimball A W., Karp J E., Dragon L H., Burke P J. Factors affecting survival of patients with acute myelocytic leukemia presenting with high wbc counts. Cancer Treat Rep 1981 65 11-12 1007-1013 (Pubitemid 12237729)
138. Creutzig U, Ritter J, Budde M, Sutor A, Schellong G. Early deaths due to hemorrhage and leukostasis in childhood acute myelogenous leukemia. Associations with hyperleukocytosis and acute monocytic leukemia. Cancer 1987 60 12 3071-3079 (Pubitemid 18013184)
139. Cuttner J, Conjalka M S., Reilly M et al. Association of monocytic leukemia in patients with extreme leukocytosis. Am J Med 1980 69 4 555-558 (Pubitemid 11204939)
140. Scott C S., Stark A N., Limbert H J., Master P S., Head C, Roberts B E. Diagnostic and prognostic factors in acute monocytic leukaemia: an analysis of 51 cases. Br J Haematol 1988 69 2 247-252
141. Biondi A, Cimino G, Pieters R, Pui C H. Biological and therapeutic aspects of infant leukemia. Blood 2000 96 1 24-33 (Pubitemid 30456446)
142. Stucki A, Rivier A S., Gikic M, Monai N, Schapira M, Spertini O. Endothelial cell activation by myeloblasts: molecular mechanisms of leukostasis and leukemic cell dissemination. Blood 2001 97 7 2121-2129 (Pubitemid 32239095)
143. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med 1993 329 10 673-682
144. Beek A M., Nijveldt R, van Rossum A C. Intramyocardial hemorrhage and microvascular obstruction after primary percutaneous coronary intervention. Int J Cardiovasc Imaging 2010 26 1 49-55
145. Patel B, Fisher M. Therapeutic advances in myocardial microvascular resistance: unravelling the enigma. Pharmacol Ther 2010 127 2 131-147
146. Bhavsar J, Rosenson R S. Adenosine transport, erythrocyte deformability and microvascular dysfunction: an unrecognized potential role for dipyridamole therapy. Clin Hemorheol Microcirc 2010 44 3 193-205
147. Bekkers S C., Yazdani S K., Virmani R, Waltenberger J. Microvascular obstruction: underlying pathophysiology and clinical diagnosis. J Am Coll Cardiol 2010 55 16 1649-1660
148. Buja L M. Myocardial ischemia and reperfusion injury. Cardiovasc Pathol 2005 14 4 170-175 (Pubitemid 40977859)
149. Khouri R K. Free flap surgery. The second decade. Clin Plast Surg 1992 19 4 757-761
150. Ashjian P, Chen C M., Pusic A, Disa J J., Cordeiro P G., Mehrara B J. The effect of postoperative anticoagulation on microvascular thrombosis. Ann Plast Surg 2007 59 1 36-39, discussion 3940 (Pubitemid 46987974)
151. Radomski M W., Palmer R M., Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 1987 2 8567 1057-1058 (Pubitemid 17154788)
152. Azizzadeh B, Buga G M., Berke G S., Larian B, Ignarro L J., Blackwell K E. Inhibitors of nitric oxide promote microvascular thrombosis. Arch Facial Plast Surg 2003 5 1 31-35
153. Miyakis S, Lockshin M D., Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006 4 2 295-306
154. Cervera R, Piette J C., Font J et al, Euro-Phospholipid Project Group. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002 46 4 1019-1027 (Pubitemid 34303815)
155. Espinosa G, Cervera R. Antiphospholipid syndrome: frequency, main causes and risk factors of mortality. Nat Rev Rheumatol 2010 6 5 296-300
156. Mehdi A A., Salti I, Uthman I. Antiphospholipid syndrome: endocrinologic manifestations and organ involvement. Semin Thromb Hemost 2011 37 1 49-57
157. Cervera R, Asherton R A. Catastrophic antiphospholipid syndrome. Pathophysiol Haemost Thromb 2006 35 1-2 181-186
158. Asherson R A., Cervera R, Piette J C. et al. Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients. Medicine (Baltimore) 1998 77 3 195-207 (Pubitemid 28290020)
159. Asherson R A., Cervera R, Piette J C. et al. Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. Medicine (Baltimore) 2001 80 6 355-377 (Pubitemid 33070843)
160. Cervera R, Khamashta M A., Shoenfeld Y et al, Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies). Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 2009 68 9 1428-1432
161. Bucciarelli S, Erkan D, Espinosa G, Cervera R. Catastrophic antiphospholipid syndrome: treatment, prognosis, and the risk of relapse. Clin Rev Allergy Immunol 2009 36 2-3 80-84
162. Stein S C., Smith D H. Coagulopathy in traumatic brain injury. Neurocrit Care 2004 1 4 479-488 (Pubitemid 41278339)
163. Astrup T. Assay and content of tissue thromboplastin in different organs. Thromb Diath Haemorrh 1965 14 3-4 401-416
164. Goodnight S H., Kenoyer G, Rapaport S I., Patch M J., Lee J A., Kurze T. Defibrination after brain-tissue destruction: A serious complication of head injury. N Engl J Med 1974 290 19 1043-1047
165. Jacoby R C., Owings J T., Holmes J, Battistella F D., Gosselin R C., Paglieroni T G. Platelet activation and function after trauma. J Trauma 2001 51 4 639-647 (Pubitemid 33029277)
166. Nekludov M, Antovic J, Bredbacka S, Blombäck M. Coagulation abnormalities associated with severe isolated traumatic brain injury: cerebral arterio-venous differences in coagulation and inflammatory markers. J Neurotrauma 2007 24 1 174-180 (Pubitemid 46214423)
167. Dietrich W D. Morphological manifestations of reperfusion injury in brain. Ann N Y Acad Sci 1994 723 15-24 (Pubitemid 24228131)
168. Dietrich W D., Alonso O, Halley M. Early microvascular and neuronal consequences of traumatic brain injury: a light and electron microscopic study in rats. J Neurotrauma 1994 11 3 289-301 (Pubitemid 24282554)
169. Maeda T, Katayama Y, Kawamata T, Aoyama N, Mori T. Hemodynamic depression and microthrombosis in the peripheral areas of cortical contusion in the rat: role of platelet activating factor. Acta Neurochir Suppl (Wien) 1997 70 102-105 (Pubitemid 127502065)
170. Stein S C., Graham D I., Chen X H., Smith D H. Association between intravascular microthrombosis and cerebral ischemia in traumatic brain injury. Neurosurgery 2004 54 3 687-691, discussion 691 (Pubitemid 38298743)
171. Kaufman H H., Hui K S., Mattson J C. et al. Clinicopathological correlations of disseminated intravascular coagulation in patients with head injury. Neurosurgery 1984 15 1 34-42 (Pubitemid 14055056)
172. Kushimoto S, Yamamoto Y, Shibata Y, Sato H, Koido Y. Implications of excessive fibrinolysis and alpha(2)-plasmin inhibitor deficiency in patients with severe head injury. Neurosurgery 2001 49 5 1084-1089, discussion 10891090
173. Grenander A, Bredbacka S, Rydvall A et al. Antithrombin treatment in patients with traumatic brain injury: a pilot study. J Neurosurg Anesthesiol 2001 13 1 49-56 (Pubitemid 32104102)
174. Wahl F, Grosjean-Piot O, Bareyre F, Uzan A, Stutzmann J M. Enoxaparin reduces brain edema, cerebral lesions, and improves motor and cognitive impairments induced by a traumatic brain injury in rats. J Neurotrauma 2000 17 11 1055-1065
175. Dudley R R., Aziz I, Bonnici A et al. Early venous thromboembolic event prophylaxis in traumatic brain injury with low-molecular-weight heparin: risks and benefits. J Neurotrauma 2010 27 12 2165-2172
176. Roos Y B., de Haan R J., Beenen L F., Groen R J., Albrecht K W., Vermeulen M. Complications and outcome in patients with aneurysmal subarachnoid haemorrhage: a prospective hospital based cohort study in the Netherlands. J Neurol Neurosurg Psychiatry 2000 68 3 337-341 (Pubitemid 30248708)
177. Vergouwen M D., Vermeulen M, Coert B A., Stroes E S., Roos Y B. Microthrombosis after aneurysmal subarachnoid hemorrhage: an additional explanation for delayed cerebral ischemia. J Cereb Blood Flow Metab 2008 28 11 1761-1770
178. Romano J G., Forteza A M., Concha M et al. Detection of microemboli by transcranial Doppler ultrasonography in aneurysmal subarachnoid hemorrhage. Neurosurgery 2002 50 5 1026-1030, discussion 10301031
179. Giller C A., Giller A M., Landreneau F. Detection of emboli after surgery for intracerebral aneurysms. Neurosurgery 1998 42 3 490-493, discussion 493494
180. Crompton M R. The pathogenesis of cerebral infarction following the rupture of cerebral berry aneurysms. Brain 1964 87 491-510
181. Stein S C., Browne K D., Chen X H., Smith D H., Graham D I. Thromboembolism and delayed cerebral ischemia after subarachnoid hemorrhage: an autopsy study. Neurosurgery 2006 59 4 781-787, discussion 787788 (Pubitemid 44579595)
182. Wurm G, Tomancok B, Nussbaumer K, Adelwöhrer C, Holl K. Reduction of ischemic sequelae following spontaneous subarachnoid hemorrhage: a double-blind, randomized comparison of enoxaparin versus placebo. Clin Neurol Neurosurg 2004 106 2 97-103 (Pubitemid 38299271)
183. Roos Y, STAR Study Group. Antifibrinolytic treatment in subarachnoid hemorrhage: a randomized placebo-controlled trial. Neurology 2000 54 1 77-82 (Pubitemid 30038741)
184. Chwajol M, Starke R M., Kim G H., Mayer S A., Connolly E S. Antifibrinolytic therapy to prevent early rebleeding after subarachnoid hemorrhage. Neurocrit Care 2008 8 3 418-426
185. Starke R M., Kim G H., Fernandez A et al. Impact of a protocol for acute antifibrinolytic therapy on aneurysm rebleeding after subarachnoid hemorrhage. Stroke 2008 39 9 2617-2621
186. Pabinger I, Karnik R, Lechner K, Slany J, Niessner H. Coumarin induced acral skin necrosis associated with hereditary protein C deficiency. Blut 1986 52 6 365-370 (Pubitemid 16091075)
187. McGehee W G., Klotz T A., Epstein D J., Rapaport S I. Coumarin necrosis associated with hereditary protein C deficiency. Ann Intern Med 1984 101 1 59-60 (Pubitemid 14088071)
188. Rose V L., Kwaan H C., Williamson K, Hoppensteadt D, Walenga J, Fareed J. Protein C antigen deficiency and warfarin necrosis. Am J Clin Pathol 1986 86 5 653-655 (Pubitemid 17181369)
189. Sallah S, Abdallah J M., Gagnon G A. Recurrent warfarin-induced skin necrosis in kindreds with protein S deficiency. Haemostasis 1998 28 1 25-30 (Pubitemid 29059507)
190. Dahlbäck B. New molecular insights into the genetics of thrombophilia. Resistance to activated protein C caused by Arg506 to Gln mutation in factor V as a pathogenic risk factor for venous thrombosis. Thromb Haemost 1995 74 1 139-148
191. Kiehl R, Hellstern P, Wenzel E. Hereditary antithrombin III (AT III) deficiency and atypical localization of a coumarin necrosis. Thromb Res 1987 45 2 191-193 (Pubitemid 17008087)
192. Fluri S, Kaczala G W., Leibundgut K, Alberio L. Chickenpox is not always benign: postvaricella purpura fulminans requires prompt and aggressive treatment. Pediatr Emerg Care 2010 26 12 932-934
193. Sharma V K., Dubey T N., Dave L, Agarwal A. Postvaricella purpura fulminans with no evidence of disseminated intravascular coagulation (DIC) or protein S deficiency. J Indian Med Assoc 2010 108 8 529-530
194. Francis R B. Jr. Acquired purpura fulminans. Semin Thromb Hemost 1990 16 4 310-325
195. Josephson C, Nuss R, Jacobson L et al. The varicella-autoantibody syndrome. Pediatr Res 2001 50 3 345-352 (Pubitemid 32801959)
196. Manco-Johnson M J., Nuss R, Key N et al. Lupus anticoagulant and protein S deficiency in children with postvaricella purpura fulminans or thrombosis. J Pediatr 1996 128 3 319-323 (Pubitemid 26087529)
197. Busuttil D P., Hay C R., Lewis M A., Wynn R F. Aggressive multiple modality therapy for varicella-associated purpura fulminans. Br J Haematol 2000 110 4 1012-1013